"The intention of this agreement is to take the weapons option off the table for the next 25 years, and the agreement does that"
But.....dont let facts and experts get in the way of your rhetoric baggers!
Aaron Stein, a nuclear nonproliferation expert at the Royal United Services Institute. Stein is a prolific writer and commenter on nuclear issues, and particularly on Iran's nuclear program. (He is also doctoral fellow at the Geneva Centre for Security Policy and a non-resident fellow at the Atlantic Council.) And he is a die-hard wonk — someone who cares first and foremost about understanding the issues, rather than about picking a side.
Even in the face of OCMPLETE OBSTRUCTION by the GOP, Obama finds a way to get it done.
Oh yeah, all of your retirement accounts can thank Obama for his amazing and historic BULL MARKET as well!!!!
Nuclear proliferation expert from Minnesota calls Iran deal 'a pretty good outcome'
Mark Fitzpatrick, The International Institute for Strategic Studies in London, was a veteran of the Foreign Service before joining the London think tank.
- "I would give it an A": Why nuclear experts love the Iran deal.
- The thing I was saying at the time was, "The fact sheet looks great, good luck getting that on paper." And then they did it.
- "I see it as a really straightforward measure to slow down an enrichment program that was going gangbusters"
Jeffrey Lewis is a nukes super nerd: He's the director of the East Asia Nonproliferation Program at the Monterey Institute of International Studies, and also runs an excellent arms control blog network and arms control podcast and has a regular arms control column in Foreign Policy.
FOX is run by the GOP establishment. It was obvious to me that the GOP establishment does NOT want Trump to last long. So they gave the moderators questions that tried to make him look bad.
If you look at the 8k, the total possible raise for this round is $2mil. They only got $350k on the first filing but they are getting more out of this one. Watch for more filings in the next couple days.
This per the company.
Yeah, and those sales numbers are VERY VERY VERY conservative and are based on 0% sales growth.....again, conservative.
Overall, a very nice report!
Now, get the money. so we can start BFPET P2, and finish CardioPET P2 ALREADY!!!!
And how about that $60 trade at the EOD by NITE to being it down to a $0.30 close.
C'mon Spoor and co., AT LEAST give is an update on progress. The SEC filings arent enough. Yes, we can keep up with the financials and GUESS what you do with the money you have and if you are still actively trying to raise money through the open note, but we shouldnt have to guess.
For example: are you using the money to fund CardioPET P2 results? Will you be presenting them at a conference first, or releasing a PR? Are you spending the money on getting BFPET P2 going? Has enrollment started? If not, when? Aside from the obvious (getting results) what are you doing to get the word out on FPMI? Those little analyst reports from One Equity Research are cute and all, but we need REAL analyst coverage. What are you doing to attract that?
C'MON ALREADY!!!! LETS GO!!!!!!!!!!!
Lets hope so. It was a good idea to do 1 last bridge loan instead of trying to raise money at this low pps.
Lets hope they get enough to fund CardioPET P2 results and to get some data for BFPET P2, so they dont have to do a public raise until at minimum, interim results for BFPET P2 are in.
I dont think you understand the situation here.
This private placement is for up to $2mil per the 8k. They just raised $350k out of the possible $2mil. They are still raising money through this private placement.........it aint done.
IMO, they will be able to get enough to get both CardioPET p2 data done and start and get interim P2 data for BFPET (I am guessing they need ~$1mil to do this).
Once data starts coming in for the P2s the pps will increase to reflect the new situation. Also, larger companies that want this tech want the P2 data, so they will also have the option of licensing out 1 to fund the other.....something I have always thought will happen here.
Check the filing from yesterday. It mentions both Merriman Capital and Highline Reseacrh Advisors (which is woned by Merriman) in Section 12, Sales Compensation.
It looks like Merriman will help them raise the rest of the $2mil from this private placement.
I would assume an analyst and thus additional coverage will come with them.
A little about Merriman:
Over the past 10 years, Merriman Capital has closed investment banking transactions worth more than nine billion dollars. Headquartered in San Francisco and New York, the firm is also the leading investment bank for OTCQX-listed companies, having more OTCQX listings than any competing investment bank. Merriman Capital’s parent company, Merriman Holdings, Inc. (OTCQB: MERR), trades on OTCQB.
We generate quality advice and service on behalf of our clients through four business segments: Corporate Services Advisory, Institutional Trading Execution, Investment Banking and Financial Entrepreneur Platform.
The Merriman team has the extensive institutional relationships, knowledge, and experience needed to advise corporate clients on complex capital market issues. We are contrarians—focusing on areas of the marketplace that mainstream investors do not see—and are recognized for our sector expertise in industrial efficiency, “disruptive” and materials technologies, telecommunications, resources, and consumer innovation.
Merriman wrote the first report on Stratasys (NASDAQ – SSYS) when we were a $29mm market cap with no other research coverage or sponsorship. They were the first investment bank to the table, and really got behind our story early and worked relentlessly to present our value proposition to potential investors. Merriman also helped us with two significant financings in our early days, and we have always greatly valued their advice on capital markets related issues. I’ve known Jon Merriman since 2002 and respect and appreciate his efforts on behalf of the entrepreneur.
– Scott Crump, founder and CEO, Stratasys LTD
What is most interesting and telling to me is that this note is separate from the $2mil note that is still open and (according to IR) still bringing in money. Interestingly, this note does not involve warrants, like the other does. Just high interest rate that doesnt mean anything in real cash terms due to the 1 month term of the note.
What it tells me is that they are moving forward with the CardioPET results, likely paying the CRO what is needed to perform the blinded read. Once that info comes in, they can PR it and get the remaining money on the $2mil note needed to completely pay off the CRO, get the final report and get the P2 BFPET trial rolling.
I would also expect this note to be payed off with the proceeds from the $2mil note once they can PR the blinded read results and finish off the $2mil note (note: based on the info in the filings and educated guesses, they need around $1-$1.2mil to get CardioPET P2 results and start BFPET P2. Since they already have $550k, that lowers it to around $500-700k needed from the $2mil note.
Its getting closer.......LETS GO ALREADY!!!!!!!!!!!!!!!
Agree 100%. They should be looking at deals for CardioPET to fund BFPET P2 and beyond, based on the revised revenue projections.They can shop around all they want, but until they have and present P2 data, noone is going to touch it. P2 is the derisking phase for buyers. Buyers/dealmakers want the P2 data......as do the shareholders.
You dont sit on good data if you have it. You scream it from the rooftops.....especially companies caught in a financial catch-22 like this one is.
My bet is placed - I think we see good P2 CardioPET data within a couple of weeks, now that they have the cash. This financial snafu shook the CEO and company execs, and wont be repeated. They are now doing what it takes to get the milestones hit (P2 CardioPET results, start P2 for BFPET and securing enough financing so people doing their DD dont have a reason not to buy and enough to push PFPET to market).
As always, do your own DD, and as always, LETS GO ALREADY!!!!!!!!!!
I will give you the facts as per the 8k.
Per the 8k filed on June 3rd, this was another private placement using promissory notes. The filing was for up to $2mil. The $350k that was raised was part of this private placement and happened at $0.35. The private placement ends 90 days from the 1st closing (which happened when the 8k was filed June 3rd). It had a trigger of $250k. In other words, after $250k was raised, it triggered a transfer from the escrow account to FPMI, and they legally had to file this 8k. This private placement is still open and still raising money and will continue to be open for 85 days. So, they rest of the $1m I mentioned and you asked about should be coming from THIS placement at $0.35, not a subsequent placement or offering. I hope this helps.
From the 8k:
Closing Date; Issuance of Notes and Warrants; Registration Rights.
(a) The initial closing (the “Initial Closing”) of the purchase and sale of the Notes and Warrants (as defined below) to be acquired by the Purchasers from the Company under this Agreement shall take place at such time as Purchasers have executed this Agreement to purchase at least $250,000 of principal amount of Notes, the Purchase Price has been transmitted by wire transfer or otherwise credited to or for the benefit of the Company and upon the satisfaction or waiver of all other conditions to closing set forth in this Agreement. After the Initial Closing, the Company may conduct any number of additional closings (each, an “Additional Closing” and, together with the Initial Closing, a “Closing”) so long as the final Additional Closing occurs on or before the 90th day following the Initial Closing Date. The minimum subscription amount for any Purchaser is $50,000, which may be waived by the Company in its sole discretion.
Agree. It is WAY under the radar. I think it has to do with a couple of things: (and am basing my investment on being right about these assumptions):
1) This is the only public pure play molecular imaging agent company and not many people know, understand or know how to valuate a company like this
2) It has been so long since a milestone was hit, even investors that had it on their radars arent following it anymore, or (unlike me) are waiting for management to prove themselves
3) cash position (or lack thereof)
If the data continue to show what they have shown, and their revenue projections are even close to what they project, we will be handsomely rewarded for our patience.
Like you, I like the way the financing has been done to date, ie., limiting dilution. However, once the CardioPET results are released, and PFPET P2 is started, they should be doing a raise just after interim results, which from what Im told, should be by year's end, given that the trial is at Mass Gen. (a lot of fat people in Mass, so it should go quickly).
Again.......LETS GO ALREADY!!!!!!
They now have enough to get the CardioPET results, IMO.
Since all the data was there, they need a blinded read and final report.
Guessing another 2 weeks for data, and they usually wait until a major conference or publication to make the data public, but not sure thats possible this time.
LETS GO ALREADY!!!!!